Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03001817 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Normal Renal Function
A Phase 3 study of Severe Hypertriglyceridemia, sponsored by Kowa Research Institute.
- Completed
- Registry status
- Phase 3
- Development phase
- 551
- Enrollment target
- 20
- Study locations
NCT03001817 is a Phase 3 study of Severe Hypertriglyceridemia that has completed, run by Kowa Research Institute. The registered enrollment target is 551 participants, above the 356-participant average among 8 other Severe Hypertriglyceridemia trials with a reported enrollment target (55% higher). The trial reports 20 study locations across 6 states.
The verdict
NCT03001817, a Phase 3 study of Severe Hypertriglyceridemia, has completed, sponsored by Kowa Research Institute.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 551 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of K-877 in adult patients with fasting high triglyceride levels ≥500 mg/dL and \<2000 mg/dL and normal renal function.
Conditions Studied
Interventions
- DRUG Fenofibrate
- DRUG K-877
- DRUG Placebo (for K-877)
- DRUG Placebo (for Fenofibrate)
Study Locations (20)
Alabama
- Central Research Associates, Inc. - Birmingham
- Central Alabama Research - Birmingham
- Cahaba Research, Inc. - Birmingham
- Boyett Health Services Inc - Hamilton
- Longwood Research - Saadat Ansari, MD, LLC - Huntsville
- Terence T. Hart, MD - Tuscumbia
California
- Advanced Research Center - Anaheim
- Torrance Clinical Research Institute Inc. - Lomita
- Downtown L.A. Research Center, Inc. - Los Angeles
- Catalina Research Institute, LLC - Montclair
- Lucita M. Cruz, MD., Inc. - Norwalk
Arizona
- Arrowhead Health Centers - Glendale
- Phoenix Medical Research Institute, LLC - Peoria
- Elite Clinical Studies - Phoenix
- Clinical Research Institute of Arizona, LLC - Surprise
Arkansas
- iResearch - Little Rock - Little Rock
- Lynn Institute of the Ozarks - Little Rock
Florida
- Atlantic Clinical Research Collaborative - Boynton Beach
- ALL Medical Research, LLC - Cooper City
Colorado
- Creekside Endocrine Associates, PC - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 551 participants |
| Start Date | 2016-11-28 |
| Est. Completion | 2019-06-24 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03001817
The ClinicalTrials.gov registry entry for NCT03001817 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 551 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 356-participant average among 8 other Severe Hypertriglyceridemia trials with a reported enrollment target (55% higher). The listed sponsor is Kowa Research Institute, which has 44 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Severe Hypertriglyceridemia appearing as the primary indexed condition, and to 4 interventions - of which Fenofibrate is the first listed.
NCT03001817 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Alabama, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT03001817 about?
NCT03001817 is a clinical study titled "Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Normal Renal Function". The purpose of this study is to evaluate the efficacy and safety of K-877 in adult patients with fasting high triglyceride levels ≥500 mg/dL and \<2000 mg/dL and normal renal function.
What is the current status of trial NCT03001817?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 551 participants. The study started on 2016-11-28. Estimated completion is 2019-06-24.
What conditions does trial NCT03001817 study?
This clinical trial studies the following conditions: Severe Hypertriglyceridemia.
What interventions are being tested in trial NCT03001817?
The interventions under investigation include: Fenofibrate (DRUG), K-877 (DRUG), Placebo (for K-877) (DRUG), Placebo (for Fenofibrate) (DRUG).
Who is sponsoring clinical trial NCT03001817?
This trial is sponsored by Kowa Research Institute, which has 44 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03001817 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Severe Hypertriglyceridemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis
RECRUITING · Phase 3
-
CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)
ACTIVE NOT RECRUITING · Phase 3
-
To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia
ACTIVE NOT RECRUITING · Phase 3
-
Study of Plozasiran in Adults With Severe Hypertriglyceridemia
ACTIVE NOT RECRUITING · Phase 3
-
Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.